IMMUTEP LIMITED (IMM)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

IMM - IMMUTEP LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.05
Index: ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.315

26 May
2023

-0.055

OPEN

$0.35

-14.86%

HIGH

$0.36

7,676,073

LOW

$0.30

TARGET
$0.60 90.5% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AHZ . ANP . ARX . AVH . BIO . BNO . BOT . CAU . CSL . CUV . EOF . FTT . GSS . HXL . IDT . IMU . IVX . KZA . LGP . MAP . MDC . MSB . MVP . MXC . MYX . NEU . NXS . OCC . OPT . OSL . PAL . PAR . PBP . PNV . PXS . PYC . RAC . RCE . RNO . SPL . TFC . TIS . TLX . TRP . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
IMM: 1
Title FY21
Actual		 FY22
Actual		 FY23
Forecast		 FY24
Forecast
EPS (cps) xxx - 3.8 - 4.8 xxx
DPS (cps) xxx N/A 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 N/A

Estimated Dividend Growth
(Average Of Past Three Years)

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
Title 201720182019202020212022
EPS Basic xxxxxxxxxxxxxxx-3.8
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx0.2 M
Book Value Per Share xxxxxxxxxxxxxxx10.9
Net Operating Cash Flow xxxxxxxxxxxxxxx-30.2 M
Net Profit Margin xxxxxxxxxxxxxxx-18,906.51 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201720182019202020212022
Return on Capital Employed xxxxxxxxxxxxxxx-38.50 %
Return on Invested Capital xxxxxxxxxxxxxxx-37.56 %
Return on Assets xxxxxxxxxxxxxxx-34.97 %
Return on Equity xxxxxxxxxxxxxxx-38.50 %
Return on Total Capital xxxxxxxxxxxxxxx-44.66 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-30.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201720182019202020212022
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx2 M
Total Debt xxxxxxxxxxxxxxx2 M
Goodwill - Gross xxxxxxxxxxxxxxx0 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx80 M
Price To Book Value xxxxxxxxxxxxxxx2.67

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201720182019202020212022
Capex xxxxxxxxxxxxxxx0.0 M
Capex % of Sales xxxxxxxxxxxxxxx13.45 %
Cost of Goods Sold xxxxxxxxxxxxxxx2 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx36 M
Research & Development xxxxxxxxxxxxxxx25 M
Investments - Total xxxxxxxxxxxxxxx-

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

25/05/2023

1

Speculative Buy

$0.60

90.48%

Immutep's lead drug eftilagimod alpha has demonstrated "impressive" clinical results across multiple indications, Bell Potter notes.

The broker expects the company will prioritise a chemo-free phase 3 trial for patients with PD-L1 of more than or equal to 1% ahead of metastatic breast cancer or head and neck squamous cell carcinoma indications.

The broker transfers coverage to another analyst and maintains a Speculative Buy rating with a $0.60 target.

FORECAST
Bell Potter forecasts a full year FY23 dividend of 0.00 cents and EPS of minus -4.80 cents.
Bell Potter forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -4.70 cents.
Access Stockbroker Research History >

IMM STOCK CHART

FNArena News on IMM

1
Australian Broker Call *Extra* Edition – May 23, 2023

May 23 2023 - Daily Market Reports
2
Australian Broker Call *Extra* Edition – May 08, 2023

May 08 2023 - Daily Market Reports
3
Rudi’s View: Domino’s Pizza, Newcrest & Qantas

Mar 17 2023 - Rudi's View
4
Rudi’s View: CSL, Mineral Resources, Ridley & ReadyTech

Feb 03 2023 - Rudi's View
5
Rudi’s View: Telix, Telstra, Treasury Wine & More

Jan 19 2023 - Rudi's View

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Dr Boreham’s Crucible: Chimeric Therapeutics

May 26 2023 - Small Caps
2
Avita Medical Preps For Enlarged US Opportunity

May 17 2023 - Small Caps
3
Dr Boreham’s Crucible: Radiopharm Theronostics

Apr 13 2023 - Small Caps
4
Dr Boreham’s Crucible: Avita Medical

Mar 29 2023 - Small Caps
5
Telix Pharmaceuticals’ Pipeline Full Of Promise

Mar 21 2023 - Small Caps
6
FDA Approval Puts Rocket Under Neuren Shares

Mar 16 2023 - Small Caps
7
Dr Boreham’s Crucible: Actinogen Medical

Nov 30 2022 - Small Caps
8
Dr Boreham’s Crucible: Qbiotics Group

Nov 09 2022 - Small Caps
9
Dr Boreham’s Crucible: Pharmaxis

Oct 05 2022 - Small Caps
10
Brokers Review Prospects For CSL

Sep 30 2022 - Australia